EnteroBiotix Reports Promising Phase 2a Results for Novel Microbiome Therapy in IBS-C
• EBX-102-02, a full-spectrum microbiome product, demonstrated clinically meaningful improvements over placebo in patients with moderate to severe IBS-C, showing benefits in symptom severity, stool consistency, and abdominal pain.
• The therapy was well-tolerated with primarily mild, self-limiting gastrointestinal side effects, and metagenomic sequencing confirmed significant shifts in intestinal microbiota composition that persisted during follow-up.
• Based on these positive results, EnteroBiotix plans to accelerate development with a larger Phase 2b trial later this year, potentially addressing a critical unmet need in IBS treatment.
© Copyright 2025. All Rights Reserved by MedPath